Treatment of HCV-Infected Recent Injection Drug Users in U.S. Liver Clinics
Status:
Active, not recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Direct antiviral therapy (standard of care) administered to chronic hepatitis C-infected
patients, in two hepatology clinics, who had used intravenous drugs in the past 6 months of
signing informed consent (IC). This cohort was compared to concurrently treated chronic
hepatitis C patients who were not intravenous drug users, who signed IC in these same
clinics. Follow-up expected two years after cure and relapse rates recorded.
Primary end point was SVR rate and secondary end points included reinfection rates in
follow-up period.